Biography and Research Information
OverviewAI-generated summary
Vidhi Bhanushali's research focuses on analyzing real-world health data to compare the effectiveness of different cancer treatments. Her work includes a propensity-matched TriNetX analysis investigating the cardiovascular outcomes associated with durvalumab versus pembrolizumab in patients with gastric cancer. This study, published in 2026, utilizes a large, de-identified patient dataset to identify potential differences in treatment side effects. Bhanushali collaborates with Anuradha Kunthur and Keshav Garg, both at the University of Arkansas for Medical Sciences, on this and related research.
Metrics
- Publications: 2
Selected Publications
-
POSTER: CLL-1382: Comparing Ibrutinib With Acalabrutinib and Zanubrutinib in B-Cell Malignancies: A Real-World Study of Mortality and Toxicity (2026)
-
CLL-1382: Comparing Ibrutinib With Acalabrutinib and Zanubrutinib in B-Cell Malignancies: A Real-World Study of Mortality and Toxicity (2026)
-
AI-enhanced ECG for acute coronary syndrome triage: A state-of-the-art review (2026)
-
Cardiovascular outcomes of durvalumab versus pembrolizumab in gastric cancer: A propensity-matched TriNetX analysis. (2026)
Collaboration Network
Top Collaborators
- Cardiovascular outcomes of durvalumab versus pembrolizumab in gastric cancer: A propensity-matched TriNetX analysis.
- AI-enhanced ECG for acute coronary syndrome triage: A state-of-the-art review
- CLL-1382: Comparing Ibrutinib With Acalabrutinib and Zanubrutinib in B-Cell Malignancies: A Real-World Study of Mortality and Toxicity
- CLL-1382: Comparing Ibrutinib With Acalabrutinib and Zanubrutinib in B-Cell Malignancies: A Real-World Study of Mortality and Toxicity
- POSTER: CLL-1382: Comparing Ibrutinib With Acalabrutinib and Zanubrutinib in B-Cell Malignancies: A Real-World Study of Mortality and Toxicity
- CLL-1382: Comparing Ibrutinib With Acalabrutinib and Zanubrutinib in B-Cell Malignancies: A Real-World Study of Mortality and Toxicity
- POSTER: CLL-1382: Comparing Ibrutinib With Acalabrutinib and Zanubrutinib in B-Cell Malignancies: A Real-World Study of Mortality and Toxicity
- CLL-1382: Comparing Ibrutinib With Acalabrutinib and Zanubrutinib in B-Cell Malignancies: A Real-World Study of Mortality and Toxicity
- POSTER: CLL-1382: Comparing Ibrutinib With Acalabrutinib and Zanubrutinib in B-Cell Malignancies: A Real-World Study of Mortality and Toxicity
- CLL-1382: Comparing Ibrutinib With Acalabrutinib and Zanubrutinib in B-Cell Malignancies: A Real-World Study of Mortality and Toxicity
- POSTER: CLL-1382: Comparing Ibrutinib With Acalabrutinib and Zanubrutinib in B-Cell Malignancies: A Real-World Study of Mortality and Toxicity
- CLL-1382: Comparing Ibrutinib With Acalabrutinib and Zanubrutinib in B-Cell Malignancies: A Real-World Study of Mortality and Toxicity
- POSTER: CLL-1382: Comparing Ibrutinib With Acalabrutinib and Zanubrutinib in B-Cell Malignancies: A Real-World Study of Mortality and Toxicity
- Cardiovascular outcomes of durvalumab versus pembrolizumab in gastric cancer: A propensity-matched TriNetX analysis.
- Cardiovascular outcomes of durvalumab versus pembrolizumab in gastric cancer: A propensity-matched TriNetX analysis.
- AI-enhanced ECG for acute coronary syndrome triage: A state-of-the-art review
- AI-enhanced ECG for acute coronary syndrome triage: A state-of-the-art review
- AI-enhanced ECG for acute coronary syndrome triage: A state-of-the-art review
- AI-enhanced ECG for acute coronary syndrome triage: A state-of-the-art review
- AI-enhanced ECG for acute coronary syndrome triage: A state-of-the-art review
- AI-enhanced ECG for acute coronary syndrome triage: A state-of-the-art review
- AI-enhanced ECG for acute coronary syndrome triage: A state-of-the-art review
Similar Researchers
Based on overlapping research topics